aTYR Pharma
ATYR· Manufacturing· Fiscal year ends in December
Sanjay S. Shukla, M.D., M.S. is the CEO of aTYR Pharma and was paid $3.5M in FY2025 (Dec), up 133%.
Executives3
See all- 1Sanjay S. Shukla, M.D., M.S.President and CEOFY2025
- 2Jill BroadfootChief Financial OfficerFY2025
- 3Nancy E. DenyesGeneral CounselFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allaTYR Pharma paid its 3 named executives $6.1M in total in FY2025 (Dec). CEO Sanjay S. Shukla, M.D., M.S. was paid $3.5M of that.
| Name | |||
|---|---|---|---|
| Sanjay S. Shukla, M.D., M.S.President and CEO | |||
| Jill BroadfootChief Financial Officer | |||
| Nancy E. DenyesGeneral Counsel |
of each named executive, from the Summary Compensation Table of each proxy.
Peers16
See allThe FY2025 (Dec) proxy of aTYR Pharma names 16 peer companies for pay. Among aTYR Pharma and these peers, CEO pay was the lowest of 5 and total shareholder return was 4th highest of 5.
5th highest of 5in aTYR Pharma and its pay peers, FY2025 (Dec) by CEO pay:
4th highest of 5in aTYR Pharma and its pay peers, FY2025 (Dec) by total shareholder return:
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Board3
See all- Paul Schimmel, Ph.D.Director · 20 yr on the boardIndependent—Paid as an executive
- Svetlana LucasDirector · 6 yr on the boardIndependentAudit (Chair), Nominating and Corporate Governance—Paid as an executive
- Eric BenevichDirector · 1 yr on the boardIndependentAudit, Compensation—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Mar 26, 2026 | FY2025 |
| Annual report | 10-K | Mar 5, 2026 | FY2025 |
| Proxy statement | DEF 14A | Mar 19, 2025 | FY2024 |
| Annual report | 10-K | Mar 13, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 5, 2024 | FY2023 |
| Annual report | 10-K | Mar 14, 2024 | FY2023 |
